BrightInsight Secures $13 Mn Investment to Advance AI-Enabled Medication Adherence Solutions

The fresh capital will enable rapid expansion of high-impact programmes, including the Patient App developed through its collaboration with Sanofi and its partner Regeneron, across a broad range of diseases and therapies worldwide.

BrightInsight has announced a new investment round of $13 million to accelerate the development and scaling of its AI-enabled medication persistence and adherence solutions, the digital health company said on Tuesday.

The funding round includes participation from both existing and new investors, including Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners.

According to the company, the fresh capital will enable rapid expansion of high-impact programmes, including the Patient App developed through its collaboration with Sanofi and its partner Regeneron, across a broad range of diseases and therapies worldwide.

BrightInsight said the investment comes at a time when medication non-adherence continues to pose a significant economic and clinical burden on global healthcare systems. The company highlighted that adherence rates for chronic diseases remain around 50 per cent, contributing to preventable deaths, hospitalisations, and substantial healthcare costs.

Positioning itself to address this challenge, BrightInsight said its digital health solutions aim to bridge the gap between prescription and long-term medication persistence, with a focus on improving patient outcomes while reducing strain on healthcare resources.

Says Kal Patel, BrightInsight’s CEO & Co-Founder, “We typically see 30-70% or more of invited patients participating in our deployed programs, with a similar percentage of those patients continuing to use the solutions one year later. Further, we are seeing these results across various diseases and patient populations.”

Commenting on the investment, Vijay Lathi, Managing Director at New Leaf Venture Partners, said, “Having been an early supporter of BrightInsight, it has been remarkable to watch the company’s evolution and the team’s disciplined execution to tackle this global patient challenge. Our decision to participate in this latest round was driven by the clear, measurable impact BrightInsight is already delivering in the patient support landscape. The Company has proven they can scale a platform that solves a critical market need, and we are proud to increase our commitment as they enter this next phase of growth.”

Building on its existing scale, BrightInsight said it will use the new funding to advance its product and solution roadmap by incorporating artificial intelligence across its platform, expanding disease-specific partnerships, and extending support to additional stakeholders such as caregivers and nurse educators.

“Patient engagement and medication adherence remain some of the most stubborn challenges in healthcare. The unique, real-world data generated on the BrightInsight platform is transforming how therapies are supported,” said Robert Zdon, Chief Operating Officer, BrightInsight. “By combining that data with advanced AI, we can better predict medication churn and deliver personalized interventions that help patients stay on therapy and achieve better outcomes.”

Stay tuned for more such updates on Digital Health News